Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches

Indian Journal of Pharmacology

Volumn 39, Issue 4, 2007, Pages 172-179

  Dixit, Nitin ^a   Baboota, Sanjula ^a   Kohli, Kanchan ^a   Ahmad, S ^a   Ali, Javed ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Bioavailability; Drug delivery; Hepatoprotection; Milk thistle; Silymarin

Indexed keywords

4 CHROMANONE DERIVATIVE; ALCOHOL; AMANITIN; BETA CYCLODEXTRIN; BOSWELLIC ACID; CYANOGINOSIN; CYCLODEXTRIN; DOXORUBICIN; ERYTHROMYCIN ESTOLATE; GLYCEROL OLEATE; INDOMETACIN; LIGNAN DERIVATIVE; LIPOSOME; PARACETAMOL; PHENYLHYDRAZINE; PHOSPHOLIPID; PLACEBO; POLYSORBATE 20; POLYSORBATE 80; PROPYLENE GLYCOL; RNA POLYMERASE; SILIBININ; SILIBININ PHOSPHATIDYLCHOLINE COMPLEX; SILIDIANIN; SILIPHOS; SILYCHRISTINE; SILYMARIN; TERT BUTYL HYDROPEROXIDE; THIOACETAMIDE; TOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE HEPATITIS; ALCOHOL LIVER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTHRITIS; BILE FLOW; BILE SECRETION; BINDING SITE; BLOATING; CANCER; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CHRONIC HEPATITIS; CLINICAL TRIAL; COLLAPSE; CONTINUOUS INFUSION; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DYSPEPSIA; ENZYME ACTIVATION; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPOSOMAL DELIVERY; LIVER CELL MEMBRANE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER PROTECTION; LIVER REGENERATION; LIVER TOXICITY; LOW DRUG DOSE; NAUSEA; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATION; PROTEIN SYNTHESIS; PSORIASIS; REVIEW; SIDE EFFECT; SILYBUM MARIANUM; TOXICITY TESTING; VIRUS HEPATITIS;

EID: 35548971992     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.36534     Document Type: Review

References (106)

1. Luper S. A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev 1998;3:410-21.
2. Pepping J. Milk thistle: Silybum marianum. Am J Health Syst Pharm 1999;56:1195-7.
3. Therapeutic products program (Health Canada) Drug product database. Available from: http://www.hc-sc.gc.ca/hpd-dgps/therapeut/htmleng/dpd.html. [Last accessed on 2000 Feb].
4. Saler R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035-63.
5. Bisset N. In: Herbal Drugs and Pharmaceuticals. CRC Press: London; 1994. p. 121-3.
6. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines: Medical Economics Company, Inc: Montvale NJ; 1998. p. 1138-41.
7. Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung 1992;42:964-8.
8. Tyler V. Phytomedicines in Western Europe: their potential impact on herbal medicine in the United States. Herbalgram 1994;30:24-30.
9. Morazzoni P, Montalbetti A, Malandrino S, Pifferi G. Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metabol Pharmacokinet 1993;18:289-97.
10. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: A silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 2005;10:193-203.
11. Arcari M, Brambilla A, Brandt A, Caponi R, Corsi G, Di Rella M, et al. A new inclusion complex of silibinin and beta-cyclodextrins:in vitro dissolution kinetics and in vivo absorption in comparison with traditional formulations. Boll Chim Farm 1992;131:205-9.
12. Morazzoni P, Bombardelli E. Silybum marianum (cardus marianus). Fitoterpia 1994;66:3-42.
13. Lecomte J. Pharmacologic properties of silybin and silymarin. Rev Med Liege 1975;30:110-4.
14. Desplaces A, Choppin J, Vogel G. The effects of silymarin on experimental phalloidine poisoning. Arzneimittelforschung 1975;25:89-96.
15. Saler R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035-63.
16. Lettéron P, Labbe G, Degott C, Berson A, Fromenty B, Delaforge M, et al. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Biochem Pharmacol 1990;39:2027-34.
17. Muriel P, Mourelle M. Prevention by silymarin of membrane alterations in acute carbon tetrachloride liver damage. J Appl Toxicol 1990;10:275-9.
18. Sharma A, Chakraborti KK, Handa SS. Antihepatotoxic activity of some herbal formulations as compared to silymarin. Fitoterapia 1991;62:229-35.
19. Mourelle M, Franco MT. Erythrocyte defects precede the onset of carbon tetrachloride-induced liver cirrhosis: Protection by silymarin. Life Sci 1991;48:1083-90.
20. Mourelle M, Muriel P, Favari L, Franco T. Prevention of carbon tetrachloride-induced liver cirrhosis by silymarin. Fundam Clin Pharmacol 1989;3:183-91.
21. Favari L, Perez-Alvarez V. Comparative effects of colchicines and silymarin on carbon tetrachloride chronic liver damage in rats. Arch Med Res 1997;28:11-7.
22. Valezuela A, Barria T, Guerra R, Garrido A. Inhibitory effect of the flavonoid silymarin on the erythrocyte hemolysis induced by phenylhydrazine. Biochem Biophys Res Commun 1985;126:712-8.
23. Valenzuela A, Guerra R, Garrido A. Silybin dihemisuccinate protects rat erythrocytes against phenylhydrazine-induced lipid peroxidation and hemolysis. Planta Med 1987;53:402-5.
24. 2+-ADP and t-butyl hydroperoxide-induced microsomal lipid peroxidation. Experientia 1986;42:139-41.
25. Davila JC, Lenherr A, Acosta D. Protective effect of flavonoids on the drug-induced hepatotoxicity in vitro. Toxicology 1989;57:267-86.
26. Farghali H, Kamenikova L, Hynie S. Silymarin effects of intracellular calcium and cytotoxicity: A study in perfused rat hepatocytes after oxidative stress injury. Pharmacol Res 2000;41:231-7.
27. Thakur SK. Silymarin-A hepatoprotective agent. Gastroenterol Today 2002;6:78-82.
28. Wang M, Grange LL, Tao J. Hepatoprotective properties of Silybum marianum herbal formulation on ethanol induced liver damage. Fitoterpia 1996;67:167-71.
29. Valenzuela A, Lagos C, Schmidt K, Videla LA. Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat. Biochem Pharmacol 1985;34:2209-12.
30. Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of flavanoid silymarin and its structural isomer silibinin. Biol Res 1994;27:105-12.
31. Siegers CP, Fruhling A, Younes M. Influence of dithiocarb, (+)-catechin and silybine on halothane hepatotoxicity in the hypoxic rat model. Acta Pharmacol Toxicol (Copenh) 1983;53:125-9.
32. Schriewer H, Weinhold F. The inß uence of silybin from Silybum marianum (L.) gaertn. on in vitro phosphatidylcholine biosynthesis in rat livers. Arzneimittelforschung 1973;29:791-2.
33. Hahn G, Lehmann HD. Kurten M. Zur pharmakologie und toxikologie von silymarin, des antihepatotoxischen wirkprinzipes aus Silybum marianum (L.) gaertn. Arzneimittelforschung 1968;18:698-704.
34. Saraswat B, Visen PKS, Patnaik GK, Dhawan BN. Effect of andrographolid against galactosamine-induced heaptotoxicity. Fototerpia 1995;66:415-20.
35. Datta S, Sinha S, Bhattacharya P. Hepatoprotective activity of a herbal protein CI-1, purified from cajanus indicus against α-galactosamine HCl toxicity in isolated rat hepatocytes. Phytother Res 1999;13:508-12.
36. Barbarino F, Neumann E, Deaciuc I, Ghelberg NW, Suciu A, Cotutiu C, et al. Effect of silymarin on experimental liver lesions. Med Interne 1981;19:347-57.
37. Farghali H, Kamenikova L, Hynie S, Kmonicková E. Silymarin effects of intracellular calcium and cytotoxicity: A study in perfused rat hepatocytes after oxidative stress injury. Pharmacol Res 2000;41:231-7.
38. Tyutyulkova N, Gorantcheva U, Tuneva S, Chelibonova-Lorer H, Gavasova E, Zhivkov V. Effect of silymarin (carsil) on the microsomal glycoprotein and protein biosynthesis in liver of rats with experimental galactosamine hepatitis. Methods Find Exp Clin Pharmacol 1983;5:181-4.
39. Ramelini G, Meldolesi J. Liver protection by silymarin: In vitro effect on dissociated rat hepatocytes. Arzneimittelforschung 1976;26:69-73.
40. Muriel P, Garciapina T, Perez-Alvarez V, Mourelle M. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J Appl Toxicol 1992;12:439-42.
41. Campos R, Garrido A, Guerra R, Valenzuela A. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Med 1989;55:417-9.
42. Renganathan A. Pharmaco dynamic properties of andrographolide in experimental animals. M.D. Thesis. Pharmacology. Pondicherry: Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry University; 1999.
43. Deak G, Muzes G, Lang I, Nekam K, Gonzalez-Cabello R, Gergely P, et al. Effects of two bioflavanoids on certain cellular immune reactions in vitro. Acta Physiol Hung 1990;76:113-21.
44. Davila JC, Lenherr A, Acosta D. Protective effect of flavonoids on drug induced hepatotoxicity in vitro. Toxicology 1989;57:2576-86.
45. Mereish KA, Bunner DL, Ragland DR, Creasia DA. Protection against microcystin-LR-induced hepatotoxicity by silymarin: Biochemistry, histopathology and lethality. Pharm Res 1991;8:273-7.
46. Floersheim GL, Eberhard M, Tschumi P, Duckert F. Effects of penicillin and silymarin on liver enzymes and blood clotting factors in dogs given a boiled preparation of Amanita phalloids. Toxicol Appl Pharmacol 1978;46:455-62.
47. De La Puerta R, Martinez E, Bravo L, Ahumada MC. Effect of silymarin on different acute inflammation models on leukocyte migration. J Pharm Pharmacol 1996;48:968-70.
48. Fiebrich F, Koch H. Silymarin, an inhibitor of lipoxygenase. Experientia 1979;35:1548-60.
49. Fiebrich F, Koch H. Silymarin, an inhibitor of primase synthetase. Experientia 1979;35:1550-2.
50. Gupta OP, Sing S, Bani S, Sharma N, Malhotra S, Gupta BD, et al. Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine 2000;7:21-4.
51. Škottováa N, Krečmanb V, Váňaa P, Chmelac Z, Ulrichováb J, Šimánekb V. Effect of silymarin and silibinin-phosphatidylcholine complex on plasma and lipoprotein cholesterol and oxidation of LDL in rats fed on high cholesterol diet supplemented with currant oil. Acta Univ Palacki Olomuc Fac Med 2000;144:55.
52. Lirussi F, Beccarello A, Zanette G, De Monte A, Donadon V, Velussi M, et al. Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. Diabetes Nutr Metab 2002;15:222-31.
53. Kim YC, Kim EJ, Lee ED, Kim JH, Jang SW, Kim YG, et al. Comparative bioavailability of silibinin in healthy male volunteers. Int J Clin Pharmacol Ther 2003;41:593-6.
54. Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 1990;15:333-8.
55. Vailati A, Aristia L, Sozze E, Milani F, Inglese V, Galenda P. Randomized open study of the dose-effect relationship of a short course of IdB 1016 in patients with viral or alcoholic hepatitis. Fitoterapia 1993;44:219-8.
56. Mirguez MP, Anundi I, Sainz-Pardo LA, Lindros KO. Hepatoprotective mechanism of silymarin: No evidence for involvement of cytochrome P4502E1. Chem Biol Interact 1994;91:51-63.
57. Wagner H. Plant constituents with antihepatotoxic activity. In: Beal JL, Reinhard E, editors. Natural Products as Medicinal Agents. Stuttgart: Hippokrates-Verlag; 1981.
58. Bosisio E, Benelli C, Pirola O. Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res 1992;25:147-54.
59. Sonnenbichler J, Zetl I. Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. Progr Clin Biol Res 1986;213:319-31.
60. Baer-Dubowska W, Szaefer H, Drajka-Kuzniak V. Inhibition of murine hepatic cytochrome P450 activities by natural and synthetic phenolic compounds. Xenobiotica 1998;28:735-43.
61. Halim AB, el-Ahmady O, Hassab-Allah S, Abdel-Galil F, Hafez Y, Darwish A. Biochemical effect of antioxidants on lipids and liver function in experimentally-induced liver damage. Ann Clin Biochem 1997;34:656-63.
62. Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996;23:749-54.
63. Fantozzi R, Brunelleschi S, Rubino A, Tarli S, Masini E, Mannaioni PF. FMLP-activated neutrophils evoke histamine release from mast cells. Agents Actions 1986;18:155-8.
64. Dehmlow C, Murawski N, de Groot H. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci 1996;58:1591-600.
65. Fuchs EC, Weyhenmeyer R, Weiner OH. Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts. Arzneimittelforschung 1997;47:1383-7.
66. Deak G, Muzes G, Lang I, Niederland V, Nékám K, Gonzalez-Cabello R, et al. Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil 1990;131:1291-2.
67. Lang I, Nekam K, Gonzalez-Cabello R, Muzes G, Gergely P, Fehér J. Hepatoprotective and immunological effects of antioxidant drugs. Tokai J Exp Clin Med 1990;15:123-7.
68. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharamacology to clinical medicine. Indian J Med Res 2006;124:491-504.
69. Desplaces A, Choppin J, Vogel G, Trost W. The effects of silymarin on experimental phalloidine poisoning. Arzneimittelforschung 1975;25:89-96.
70. Carducci R, Armellino MF, Volpe C, Basil G, Caso N, Apicella A, et al. Silibinin and acute poisioning with Amanita phalloids. Minerva Anestesiol 1996;62:187-93.
71. Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres. Med Klin 1978;73:1060-5.
72. Fehér J, Deák G, Müzes G, Láng I, Niederland V, Nékám K, et al. Liver protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil 1989;130:2723-7.
73. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9:105-13.
74. Kreeman V, Skottova N, Walterova D, Ulrichová J, Simánek V. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Med 1998;64:138-42.
75. Kock HP, Bachner J, Loffler E. Silymarin: Potent inhibitor of cyclic AMP phosphodiesterase. Methods Find Exp Clin Pharmacol 1985;7:409-13.
76. Vinh PQ, Sugie S, Tanaka T, Hara A, Yamada Y, Katayama M, et al. Chemopreventive effects of a flavonoid antioxidant silymarin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Jpn J Cancer Res 2002;93:42-9.
77. Kohno H, Tanaka T, Kawabata K, Hirose I, Sugie S, Tsuda H, et al. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer 2002;101:461-8.
78. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, Agarwal R. A flavonoid antioxidant silymarin affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res 1999;59:622-32.
79. Agarwal R, Katiyar SK, Lundgren DW, Mukhtar H. Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-O-tetradecanoylphorbol- 13-acetate-induced epidermal ornitine decarboxylase activity and mRNA in SENCAR mice. Carcinogenesis 1994;15:1099-103.
80. Zhao J, Sharma Y, Agarwal RA. Flavonoid antioxidant, silymarin, affords significant inhibition against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes and cycloxygenase 2 and interleukin-1a expression in SENCAR mouse epidermis: Implications in the prevention of stage I tumor. Mol Carcinog 1999;26:321-33.
81. Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, et al. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 2002;16:2103-12.
82. Soto CP, Perez BL, Favari LP, Reyes JL. Prevention of alloxan- induced diabetes mellitus in the rat by silymarin. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998;119:125-9.
83. Soto C, Recoba R, Barron H, Alvarez C, Favari L. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem Physiol C Toxicol Pharmacol 2003;136:205-12.
84. Chlopèíková A, Psotová J, Miketová P, Šimánek V. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytother Res 2004;18:107-10.
85. Katiyar SK, Korman NJ, Mukhtar H, Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 1997;89:556-66.
86. Mallikarjuna G, Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases and Akt signaling. Cancer Res 2004;64:6349-56.
87. Silybum marianum (Milk thistle). Altern Med Rev 1999;4:272-4.
88. Jacobs PB, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver disease: A systematic review and meta-analysis. Am J Med 2002;113:506-15.
89. An adverse reaction to the herbal medication Milk thistle (Silybum marianum). Adverse reaction advisory committee. Med J Aust 1999;170:218-9.
90. Blumenthal M, Goldberg A, Brinkmann J. Herbal Medicine. Integrative Medicine Communications: Newton; 2000.
91. Comoglio A, Tomasi A, Malandrino S, Poli G, Albano E. Scavanging effect of silipide, a new silybin-phospholipid complex on ethanol derived free radicals. Biochem Pharm 1995;50:1313-6.
92. Giacomelli S, Gallo D, Apollonio P, Ferlini C, Distefano M, Morazzoni P, et al. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo activity of cisplatin. Life Sci 2002;70:1447-59.
93. Madaus R, Halbach G, Trost W. Salt of silymarin group with aminopolyhydroxy alcohols. US patent 3994925, 1976.
94. Gabetta B, Bombardelli E, Pifferi G. Complexes of flavanolignans with phospholipids, preparation thereof and associated pharmaceutical compositions. US patent 4764508, 1988.
95. Wachter W, Zaeske H. Process for the manufacture of flavanolignan preparation with improved release and absorbability, compositions obtainable thereby and their use for the preparation of pharmaceuticals. US patent 6020384, 2000.
96. Valcavi U, Monterosso V, Caponi R, Bosone E, Wachter W, Szejtli J. Inclusion complexes with silybinin, their preparation and pharmaceutical compositions containing them. US patent 5198430, 1993.
97. Chen W, Xia H, Wu W. Optimized preparation of silymarin dripping pils by a central composite design response surface method. Chin Trad Herb Drug 2005;36:679-83.
98. Koo CH. Compositions and preparations of silymarin complex with improved bioavailability. WO 02/069962, 2002.
99. Giorgi R, Conti M, Pifferi G. Soluble derivative of silybin a method of preparing them and pharmaceutical composition containing them. US patent 4886791, 1989.
100. Woo JS, Kim TS, Park JH, Chi SC. Formulation and biopharmaceutical evaluation of silymarin using SMEDDS. Arch Pharm Res 2007;30:82-9.
101. Abrol S, Trehan A, Katare OP. Comparative study of different silymarin formulations: Formulation, characterization and in vitro/in vivo evaluation. Curr Drug Deliv 2005;2:45-51.
102. Yanyu X, Yunmei S, Zhipeng C, Qineng P. The preparation of silybin-phospholipid complex and the study of its pharmacokinetics in rats. Int J Pharm 2006;307:77-82.
103. Yan-yu X, Yun-mei S, Zhi-peng C, Qi-neng P. Preparation of silymarin proliposome: A new way to increase oral bioavailability of silymarin in beagle dogs. Int J Pharm 2006;319:162-8.
104. El-Samaligy MS, Afifi NN, Mahmoud EA. Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance. Int J Pharm 2006;319:121-9.
105. Wu Wei, Wang Y, Que L. Enhanced biavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm 2006;63:288-94.
106. Haus DJ, Mehta SC, Radebaugh GW. Targeting lymphatic transport and modified systemic distribution of CI_976, a lipophilic lipid-regulator drug, via a formulative approach. Int J Pharm 1994;108:85-93.